# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 6.1 | nc | (nc-nc) |  | Male | 7 | 4.0 | 174.0 | (69.7-358.5) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 5 | 2.9 | 170.2 | (54.8-397.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 21 | 24.8 | 84.6 | (52.4-129.4) |  | Female | 5 | 2.9 | 170.8 | (55.1-398.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 6.8 | 73.8 | (23.8-172.3) |  |  |  |  |  |  |
| Female | 4 | 6.4 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 27 | 23.4 | 115.6 | (76.2-168.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 5 | 4.2 | 119.8 | (38.6-279.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 7 | 5.6 | 124.4 | (49.8-256.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 11.6 | 43.3 | (13.9-101.0) |  | Male | 67 | 84.4 | 79.4 | (61.5-100.8) |
| Female | 3 | 11.2 | nc | (nc-nc) |  | Female | 71 | 80.3 | 88.4 | (69.1-111.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

61

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 13.4 | 134.7 | (79.8-212.9) |  | Male | 9 | 8.5 | 105.3 | (48.0-199.9) |
| Female | 7 | 5.0 | 139.9 | (56.0-288.3) |  | Female | 12 | 6.9 | 174.0 | (89.8-303.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 6 | 7.6 | 79.0 | (28.8-171.9) |
| Female | 41 | 56.7 | 72.3 | (51.9-98.1) |  | Female | 14 | 7.0 | 199.8 | (109.2-335.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 6.2 | 129.6 | (55.8-255.4) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 14.2 | 105.5 | (59.0-174.1) |  |  |  |  |  |  |
| Female | 10 | 14.8 | 67.4 | (32.2-123.9) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.6 | 168.7 | (61.6-367.1) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 3 | 5.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 46 | 45.5 | 101.1 | (74.0-134.8) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 7.3 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 6 | 4.4 | 136.2 | (49.7-296.4) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 4 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 6 | 9.7 | 61.9 | (22.6-134.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 12 | 13.1 | 91.5 | (47.2-159.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 24.0 | 129.3 | (87.9-183.6) |  | Male | 175 | 175.0 | 100.0 | (85.8-116.0) |
| Female | 36 | 26.5 | 135.6 | (95.0-187.7) |  | Female | 178 | 188.1 | 94.6 | (81.2-109.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

62

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 8 | 6.1 | 131.0 | (56.4-258.2) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 21 | 25.4 | 82.6 | (51.1-126.3) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 21 | 20.6 | 101.8 | (63.0-155.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

63

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 14.2 | 98.8 | (54.0-165.8) |  | Male | 2 | 9.2 | nc | (nc-nc) |
| Female | 5 | 4.1 | 122.5 | (39.5-285.8) |  | Female | 6 | 6.6 | 90.6 | (33.1-197.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 2.8 | 179.3 | (57.8-418.5) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 5 | 1.9 | 259.9 | (83.8-606.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 9 | 8.4 | 107.3 | (49.0-203.8) |
| Female | 54 | 52.7 | 102.4 | (76.9-133.6) |  | Female | 5 | 6.1 | 81.7 | (26.3-190.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 7.0 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 16.1 | 68.2 | (34.0-122.1) |  |  |  |  |  |  |
| Female | 12 | 13.1 | 91.6 | (47.3-160.0) |  | Female | 1 | 4.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 6 | 5.1 | 118.2 | (43.2-257.4) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 6 | 4.1 | 145.0 | (53.0-315.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 27 | 48.6 | 55.6 | (36.6-80.9) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 8.0 | 112.2 | (51.2-213.0) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 3 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.8 | 86.5 | (27.9-201.8) |  | Male | 1 | 3.8 | nc | (nc-nc) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 13 | 10.4 | 124.9 | (66.4-213.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 11 | 12.0 | 91.7 | (45.7-164.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 24.7 | 81.1 | (49.5-125.3) |  | Male | 140 | 189.3 | 74.0 | (62.2-87.3) |
| Female | 31 | 21.5 | 144.3 | (98.0-204.8) |  | Female | 179 | 169.4 | 105.7 | (90.8-122.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

64

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 14.4 | 118.2 | (68.8-189.3) |  | Male | 22 | 8.1 | 270.6 | (169.5-409.7) |
| Female | 10 | 5.1 | 196.6 | (94.1-361.7) |  | Female | 11 | 5.4 | 204.9 | (102.2-366.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 5 | 2.2 | 229.0 | (73.8-534.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 5 | 7.1 | 70.1 | (22.6-163.5) |
| Female | 49 | 44.4 | 110.3 | (81.6-145.8) |  | Female | 7 | 6.4 | 110.1 | (44.1-226.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 5.3 | 152.3 | (65.6-300.2) |
| Female | 3 | 1.1 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 13.9 | 137.2 | (82.6-214.2) |  |  |  |  |  |  |
| Female | 14 | 14.1 | 99.3 | (54.2-166.5) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 7 | 4.8 | 146.7 | (58.8-302.3) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 6 | 5.1 | 118.5 | (43.3-257.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 48 | 42.5 | 112.9 | (83.2-149.6) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.4 | 93.1 | (34.0-202.7) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 4.9 | 161.7 | (69.6-318.7) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 1 | 5.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 11 | 10.5 | 104.5 | (52.1-187.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 25.4 | 86.7 | (54.3-131.3) |  | Male | 192 | 167.9 | 114.4 | (98.8-131.7) |
| Female | 27 | 26.7 | 101.0 | (66.5-146.9) |  | Female | 181 | 161.5 | 112.0 | (96.3-129.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

65

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 47 | 39.9 | 117.9 | (86.6-156.7) |  | Male | 22 | 25.5 | 86.3 | (54.1-130.7) |
| Female | 14 | 13.9 | 100.6 | (55.0-168.9) |  | Female | 25 | 19.6 | 127.7 | (82.6-188.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 7.5 | 160.1 | (82.6-279.6) |  | Male | 13 | 8.1 | 160.9 | (85.6-275.2) |
| Female | 7 | 6.1 | 115.0 | (46.1-236.9) |  | Female | 9 | 6.3 | 143.5 | (65.5-272.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 26 | 22.7 | 114.7 | (74.9-168.1) |
| Female | 173 | 156.5 | 110.6 | (94.7-128.3) |  | Female | 17 | 19.5 | 87.3 | (50.8-139.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 20 | 18.1 | 110.7 | (67.6-171.0) |
| Female | 6 | 5.2 | 114.6 | (41.8-249.4) |  | Female | 8 | 8.2 | 97.2 | (41.8-191.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 39 | 43.0 | 90.7 | (64.5-124.0) |  |  |  |  |  |  |
| Female | 47 | 41.6 | 112.9 | (83.0-150.2) |  | Female | 21 | 13.7 | 152.8 | (94.5-233.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 10.4 | 67.4 | (27.0-138.9) |  | Male | 17 | 13.9 | 122.2 | (71.2-195.7) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 16 | 13.9 | 114.9 | (65.6-186.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 117 | 128.7 | 90.9 | (75.2-109.0) |
| Female | 3 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 21.4 | 107.5 | (68.1-161.3) |  | Male | 4 | 9.3 | nc | (nc-nc) |
| Female | 9 | 12.3 | 72.9 | (33.3-138.4) |  | Female | 5 | 5.3 | 93.7 | (30.2-218.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 6.0 | 82.9 | (26.7-193.4) |  | Male | 5 | 5.0 | 100.2 | (32.3-233.9) |
| Female | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 15.8 | 107.8 | (62.8-172.7) |  | Male | 12 | 9.6 | 124.4 | (64.2-217.3) |
| Female | 22 | 11.2 | 196.5 | (123.1-297.6) |  | Female | 36 | 28.2 | 127.5 | (89.3-176.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 13.6 | 73.4 | (35.1-134.9) |  |  |  |  |  |  |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 49 | 35.4 | 138.3 | (102.3-182.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 67 | 71.1 | 94.3 | (73.1-119.7) |  | Male | 513 | 514.5 | 99.7 | (91.3-108.7) |
| Female | 76 | 75.0 | 101.4 | (79.9-126.9) |  | Female | 599 | 524.7 | 114.2 | (105.2-123.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

66

# Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 23.0 | 73.8 | (43.0-118.2) |  | Male | 8 | 16.7 | 47.8 | (20.6-94.2) |
| Female | 9 | 8.4 | 107.0 | (48.8-203.1) |  | Female | 8 | 14.3 | 56.0 | (24.1-110.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 6.3 | 127.7 | (55.0-251.6) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 6 | 4.8 | 126.2 | (46.1-274.7) |  | Female | 5 | 3.8 | 130.5 | (42.1-304.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 18 | 15.2 | 118.6 | (70.2-187.4) |
| Female | 88 | 99.8 | 88.2 | (70.7-108.6) |  | Female | 14 | 12.6 | 111.5 | (60.9-187.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 12.0 | 50.0 | (18.2-108.7) |
| Female | 7 | 4.3 | 164.0 | (65.7-337.9) |  | Female | 9 | 5.2 | 171.5 | (78.3-325.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 27.1 | 114.2 | (77.6-162.1) |  |  |  |  |  |  |
| Female | 16 | 26.5 | 60.3 | (34.5-98.0) |  | Female | 4 | 9.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.2 | 96.9 | (35.4-210.8) |  | Male | 8 | 8.3 | 96.6 | (41.6-190.3) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 18 | 8.6 | 210.5 | (124.7-332.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 59 | 78.2 | 75.5 | (57.5-97.4) |
| Female | 1 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 14.5 | 34.5 | (11.1-80.5) |  | Male | 10 | 5.7 | 176.3 | (84.4-324.2) |
| Female | 10 | 7.9 | 127.0 | (60.8-233.5) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 3.6 | 165.5 | (60.4-360.3) |  | Male | 3 | 6.8 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 11.2 | 124.5 | (68.0-208.8) |  | Male | 8 | 8.1 | 99.2 | (42.7-195.5) |
| Female | 10 | 8.1 | 123.5 | (59.1-227.1) |  | Female | 41 | 24.1 | 170.4 | (122.2-231.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 8.4 | 178.9 | (100.1-295.1) |  |  |  |  |  |  |
| Female | 7 | 2.7 | 258.4 | (103.5-532.5) |  | Female | 16 | 21.6 | 74.0 | (42.3-120.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 56 | 40.7 | 137.7 | (104.0-178.8) |  | Male | 320 | 327.0 | 97.9 | (87.4-109.2) |
| Female | 58 | 43.6 | 133.0 | (101.0-171.9) |  | Female | 354 | 341.0 | 103.8 | (93.3-115.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

67

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 4.4 | 137.9 | (50.4-300.1) |  | Male | 5 | 2.7 | 187.9 | (60.6-438.5) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 12 | 17.0 | 70.6 | (36.4-123.3) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 4.6 | 129.4 | (47.3-281.7) |  |  |  |  |  |  |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 5 | 1.5 | 333.3 | (107.4-777.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.2 | nc | (nc-nc) |  | Male | 19 | 14.8 | 128.2 | (77.2-200.3) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 5 | 4.0 | 124.0 | (40.0-289.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 7.6 | 184.5 | (100.8-309.6) |  | Male | 68 | 55.9 | 121.7 | (94.5-154.3) |
| Female | 3 | 8.0 | nc | (nc-nc) |  | Female | 40 | 56.4 | 70.9 | (50.7-96.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

68

# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 3 | 5.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 1.7 | 360.4 | (131.6-784.4) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 5.8 | 102.6 | (37.5-223.3) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 26 | 20.7 | 125.6 | (82.0-184.1) |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 14 | 18.5 | 75.7 | (41.4-127.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

69

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 5.7 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 5.3 | 94.6 | (30.5-220.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 14 | 19.0 | 73.6 | (40.2-123.4) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 10 | 18.1 | 55.1 | (26.4-101.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

70

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 66 | 65.7 | 100.4 | (77.7-127.7) |  | Male | 22 | 40.9 | 53.8 | (33.7-81.4) |
| Female | 14 | 24.2 | 57.7 | (31.5-96.9) |  | Female | 20 | 32.4 | 61.6 | (37.6-95.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 12.0 | 75.0 | (34.2-142.4) |  | Male | 14 | 12.9 | 108.2 | (59.1-181.6) |
| Female | 10 | 9.9 | 100.5 | (48.1-184.9) |  | Female | 7 | 10.8 | 65.1 | (26.1-134.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 28 | 36.4 | 76.8 | (51.0-111.0) |
| Female | 246 | 249.0 | 98.8 | (86.8-112.0) |  | Female | 33 | 33.0 | 100.0 | (68.8-140.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 32 | 28.0 | 114.2 | (78.1-161.2) |
| Female | 8 | 8.2 | 97.8 | (42.1-192.7) |  | Female | 25 | 13.7 | 183.1 | (118.5-270.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 93 | 68.4 | 136.0 | (109.8-166.6) |  |  |  |  |  |  |
| Female | 73 | 72.5 | 100.7 | (78.9-126.6) |  | Female | 31 | 22.4 | 138.1 | (93.8-196.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 16 | 16.7 | 95.7 | (54.7-155.5) |  | Male | 20 | 22.6 | 88.5 | (54.0-136.7) |
| Female | 5 | 4.7 | 107.3 | (34.6-250.4) |  | Female | 26 | 24.4 | 106.4 | (69.5-155.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 4.7 | 106.9 | (34.4-249.4) |  | Male | 141 | 206.8 | 68.2 | (57.4-80.4) |
| Female | 2 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 40 | 33.6 | 118.9 | (84.9-161.9) |  | Male | 12 | 15.1 | 79.6 | (41.1-139.0) |
| Female | 27 | 20.3 | 133.3 | (87.8-194.0) |  | Female | 13 | 9.4 | 138.8 | (73.8-237.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 9.7 | 93.0 | (42.4-176.6) |  | Male | 11 | 8.3 | 131.9 | (65.8-236.1) |
| Female | 2 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 23 | 25.8 | 89.2 | (56.5-133.9) |  | Male | 8 | 14.8 | 54.0 | (23.3-106.4) |
| Female | 12 | 19.2 | 62.7 | (32.3-109.4) |  | Female | 31 | 44.4 | 69.9 | (47.5-99.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 21.4 | 60.9 | (32.4-104.1) |  |  |  |  |  |  |
| Female | 4 | 7.5 | nc | (nc-nc) |  | Female | 53 | 56.5 | 93.9 | (70.3-122.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 142 | 116.2 | 122.2 | (103.0-144.1) |  | Male | 762 | 829.1 | 91.9 | (85.5-98.7) |
| Female | 141 | 125.8 | 112.1 | (94.3-132.2) |  | Female | 855 | 867.0 | 98.6 | (92.1-105.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

71

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 5 | 5.2 | 95.4 | (30.7-222.6) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 4.5 | 134.1 | (49.0-291.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 21 | 16.4 | 128.3 | (79.4-196.1) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 13 | 16.9 | 76.8 | (40.8-131.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

72

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 5 | 8.0 | 62.2 | (20.0-145.2) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 2.3 | 220.3 | (71.0-514.0) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 8.2 | 85.2 | (34.1-175.6) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 3 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 27 | 32.8 | 82.4 | (54.3-119.9) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 25 | 27.6 | 90.7 | (58.7-134.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

73

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 13.0 | 176.9 | (112.1-265.4) |  | Male | 4 | 8.7 | nc | (nc-nc) |
| Female | 4 | 5.8 | nc | (nc-nc) |  | Female | 8 | 8.1 | 99.0 | (42.6-195.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 5 | 7.8 | 63.9 | (20.6-149.1) |
| Female | 58 | 62.4 | 92.9 | (70.5-120.1) |  | Female | 7 | 8.1 | 86.6 | (34.7-178.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.5 | 107.5 | (43.1-221.4) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 14.5 | 110.7 | (63.2-179.8) |  |  |  |  |  |  |
| Female | 14 | 17.8 | 78.8 | (43.0-132.2) |  | Female | 3 | 5.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 4 | 1.1 | nc | (nc-nc) |  | Female | 5 | 5.9 | 84.4 | (27.2-196.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 48 | 47.0 | 102.1 | (75.3-135.4) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 7.6 | 65.5 | (21.1-153.0) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 5 | 4.9 | 101.3 | (32.7-236.5) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 5.4 | 147.5 | (63.5-290.7) |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 5 | 4.7 | 105.7 | (34.0-246.6) |  | Female | 6 | 11.4 | 52.6 | (19.2-114.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.7 | 106.3 | (34.2-248.0) |  |  |  |  |  |  |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 13 | 14.3 | 91.1 | (48.4-155.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 23.5 | 123.4 | (82.6-177.2) |  | Male | 176 | 178.6 | 98.6 | (84.5-114.3) |
| Female | 35 | 29.7 | 117.9 | (82.1-164.0) |  | Female | 196 | 214.2 | 91.5 | (79.1-105.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

74

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 9.4 | 85.2 | (36.7-167.8) |  | Male | 5 | 6.1 | 82.3 | (26.5-192.2) |
| Female | 5 | 3.2 | 155.4 | (50.1-362.7) |  | Female | 14 | 4.3 | 324.3 | (177.1-544.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.4 | 111.9 | (40.8-243.5) |
| Female | 40 | 35.0 | 114.3 | (81.7-155.7) |  | Female | 1 | 4.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.4 | 114.5 | (36.9-267.2) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 10.0 | 120.0 | (62.0-209.7) |  |  |  |  |  |  |
| Female | 5 | 9.5 | 52.7 | (17.0-123.0) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 26 | 30.6 | 85.0 | (55.5-124.6) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 5.1 | 137.7 | (55.2-283.7) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 5 | 2.8 | 177.2 | (57.1-413.4) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 8 | 6.0 | 133.1 | (57.3-262.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 8 | 8.0 | 99.7 | (42.9-196.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 17.0 | 58.9 | (28.2-108.4) |  | Male | 107 | 122.2 | 87.6 | (71.8-105.8) |
| Female | 10 | 17.3 | 57.7 | (27.6-106.2) |  | Female | 132 | 118.5 | 111.4 | (93.2-132.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

75

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 8 | 8.0 | 99.8 | (43.0-196.6) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 9 | 8.6 | 104.1 | (47.5-197.6) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 5 | 1.9 | 263.6 | (85.0-615.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 4.9 | nc | (nc-nc) |  | Male | 29 | 34.7 | 83.6 | (56.0-120.1) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 30 | 26.6 | 112.8 | (76.1-161.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

76

# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 27.1 | 103.2 | (68.5-149.1) |  | Male | 29 | 16.6 | 174.5 | (116.9-250.7) |
| Female | 7 | 9.1 | 76.6 | (30.7-157.8) |  | Female | 18 | 11.1 | 161.8 | (95.8-255.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.6 | 107.6 | (34.7-251.2) |  | Male | 5 | 5.4 | 93.3 | (30.1-217.6) |
| Female | 5 | 3.5 | 144.5 | (46.6-337.1) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 13 | 14.9 | 87.4 | (46.5-149.5) |
| Female | 114 | 89.3 | 127.6 | (105.3-153.3) |  | Female | 9 | 12.0 | 74.7 | (34.1-141.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 11.5 | 86.7 | (41.5-159.4) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 5 | 5.0 | 99.8 | (32.1-232.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 28.5 | 66.7 | (40.1-104.2) |  |  |  |  |  |  |
| Female | 35 | 27.6 | 126.7 | (88.2-176.2) |  | Female | 15 | 8.1 | 185.1 | (103.5-305.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 6.9 | nc | (nc-nc) |  | Male | 14 | 9.3 | 150.2 | (82.0-252.0) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 8 | 9.3 | 85.7 | (36.9-168.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 86 | 84.8 | 101.4 | (81.1-125.2) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 13.8 | 94.2 | (50.1-161.1) |  | Male | 3 | 6.2 | nc | (nc-nc) |
| Female | 7 | 7.3 | 96.5 | (38.6-198.8) |  | Female | 0 | 3.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 10.3 | 58.1 | (21.2-126.5) |  | Male | 2 | 5.9 | nc | (nc-nc) |
| Female | 4 | 7.0 | nc | (nc-nc) |  | Female | 12 | 13.7 | 87.6 | (45.2-153.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.8 | 68.4 | (25.0-149.0) |  |  |  |  |  |  |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 25 | 20.2 | 124.0 | (80.2-183.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 47.3 | 40.1 | (24.1-62.7) |  | Male | 295 | 338.6 | 87.1 | (77.5-97.7) |
| Female | 27 | 45.6 | 59.1 | (39.0-86.1) |  | Female | 334 | 312.9 | 106.8 | (95.6-118.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

77

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 11 | 9.5 | 116.1 | (57.9-207.8) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 7.7 | 65.1 | (21.0-151.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 29 | 28.7 | 101.0 | (67.6-145.1) |
| Female | 1 | 4.1 | nc | (nc-nc) |  | Female | 26 | 29.9 | 86.9 | (56.7-127.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

78

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 3 | 0.8 | nc | (nc-nc) |
| Female | 7 | 4.5 | 155.2 | (62.2-319.7) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 1.3 | 389.3 | (125.5-908.5) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 4.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 16 | 18.0 | 88.9 | (50.8-144.4) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 21 | 15.3 | 137.2 | (84.9-209.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

79

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 10.3 | 106.5 | (53.1-190.5) |  | Male | 8 | 6.2 | 128.3 | (55.2-252.8) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 27 | 33.2 | 81.4 | (53.6-118.4) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 10.7 | 102.8 | (51.3-184.0) |  |  |  |  |  |  |
| Female | 11 | 9.6 | 115.0 | (57.3-205.8) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 33 | 29.5 | 111.8 | (77.0-157.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 5.0 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 1 | 5.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 7 | 7.7 | 91.1 | (36.5-187.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 18.0 | 72.2 | (38.4-123.5) |  | Male | 102 | 124.5 | 81.9 | (66.8-99.4) |
| Female | 19 | 16.8 | 113.3 | (68.2-176.9) |  | Female | 94 | 114.3 | 82.2 | (66.4-100.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

80

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 37 | 35.1 | 105.3 | (74.1-145.2) |  | Male | 18 | 21.6 | 83.3 | (49.3-131.7) |
| Female | 15 | 12.3 | 121.6 | (68.0-200.5) |  | Female | 14 | 16.0 | 87.7 | (47.9-147.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 6.1 | 196.4 | (101.4-343.1) |  | Male | 4 | 6.9 | nc | (nc-nc) |
| Female | 4 | 4.9 | nc | (nc-nc) |  | Female | 4 | 5.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 14 | 19.2 | 72.8 | (39.7-122.1) |
| Female | 141 | 123.9 | 113.8 | (95.8-134.2) |  | Female | 28 | 16.5 | 169.6 | (112.7-245.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 14.7 | 95.1 | (52.0-159.6) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 7 | 6.8 | 103.3 | (41.4-212.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 36.5 | 79.4 | (53.2-114.1) |  |  |  |  |  |  |
| Female | 39 | 37.1 | 105.2 | (74.8-143.8) |  | Female | 11 | 11.1 | 99.0 | (49.3-177.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 8.8 | 125.2 | (62.4-224.0) |  | Male | 12 | 12.0 | 99.7 | (51.5-174.2) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 9 | 12.5 | 72.2 | (33.0-137.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 119 | 106.6 | 111.6 | (92.5-133.6) |
| Female | 4 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 17.6 | 141.9 | (91.8-209.5) |  | Male | 5 | 8.0 | 62.2 | (20.1-145.3) |
| Female | 8 | 10.0 | 79.6 | (34.3-156.9) |  | Female | 7 | 4.8 | 144.5 | (57.9-297.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 5.1 | nc | (nc-nc) |  | Male | 5 | 3.8 | 130.3 | (42.0-304.0) |
| Female | 0 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 13.5 | 88.9 | (45.9-155.3) |  | Male | 11 | 7.6 | 144.2 | (71.9-258.0) |
| Female | 13 | 9.7 | 133.9 | (71.2-229.0) |  | Female | 23 | 21.4 | 107.4 | (68.1-161.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 11.2 | 107.3 | (55.4-187.4) |  |  |  |  |  |  |
| Female | 6 | 3.7 | 161.1 | (58.8-350.7) |  | Female | 38 | 27.4 | 138.5 | (98.0-190.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 65 | 61.4 | 105.8 | (81.6-134.9) |  | Male | 446 | 434.9 | 102.5 | (93.2-112.5) |
| Female | 52 | 62.2 | 83.7 | (62.5-109.7) |  | Female | 467 | 432.2 | 108.1 | (98.5-118.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

81

# Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 57 | 43.1 | 132.2 | (100.1-171.3) |  | Male | 24 | 26.6 | 90.4 | (57.9-134.5) |
| Female | 17 | 15.4 | 110.1 | (64.1-176.3) |  | Female | 18 | 19.7 | 91.4 | (54.1-144.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 7.6 | 92.2 | (37.0-190.1) |  | Male | 5 | 8.3 | 60.0 | (19.3-140.0) |
| Female | 7 | 6.1 | 115.5 | (46.3-238.0) |  | Female | 5 | 6.8 | 73.7 | (23.7-171.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 21 | 24.0 | 87.6 | (54.2-133.9) |
| Female | 126 | 153.1 | 82.3 | (68.6-98.0) |  | Female | 17 | 20.6 | 82.6 | (48.1-132.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 18.3 | 87.3 | (49.9-141.7) |
| Female | 5 | 4.8 | 104.3 | (33.6-243.3) |  | Female | 13 | 8.6 | 151.7 | (80.7-259.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 42 | 45.5 | 92.4 | (66.6-124.9) |  |  |  |  |  |  |
| Female | 44 | 46.2 | 95.2 | (69.2-127.8) |  | Female | 8 | 14.0 | 57.1 | (24.6-112.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 10.8 | 101.7 | (50.7-182.0) |  | Male | 14 | 14.8 | 94.6 | (51.7-158.8) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 8 | 15.8 | 50.7 | (21.8-99.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 160 | 131.6 | 121.6 | (103.5-141.9) |
| Female | 1 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 21.7 | 110.8 | (71.0-164.9) |  | Male | 12 | 9.9 | 121.7 | (62.8-212.6) |
| Female | 15 | 12.4 | 120.7 | (67.5-199.2) |  | Female | 7 | 6.1 | 115.5 | (46.3-238.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 6.1 | 114.5 | (45.9-235.8) |  | Male | 6 | 5.7 | 105.9 | (38.7-230.4) |
| Female | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 16.8 | 101.4 | (59.0-162.4) |  | Male | 8 | 9.7 | 82.3 | (35.5-162.3) |
| Female | 8 | 12.0 | 66.9 | (28.8-131.9) |  | Female | 32 | 25.7 | 124.4 | (85.1-175.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 13.7 | 65.7 | (30.0-124.8) |  |  |  |  |  |  |
| Female | 1 | 4.7 | nc | (nc-nc) |  | Female | 37 | 35.0 | 105.7 | (74.4-145.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 69 | 74.2 | 93.0 | (72.4-117.7) |  | Male | 544 | 537.2 | 101.3 | (92.9-110.2) |
| Female | 44 | 77.4 | 56.9 | (41.3-76.3) |  | Female | 456 | 537.1 | 84.9 | (77.3-93.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

82

# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 33.0 | 106.1 | (73.9-147.5) |  | Male | 21 | 20.0 | 105.0 | (65.0-160.5) |
| Female | 11 | 12.1 | 91.1 | (45.4-163.1) |  | Female | 20 | 15.2 | 131.2 | (80.1-202.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 5.6 | 160.8 | (73.4-305.2) |  | Male | 9 | 6.4 | 140.3 | (64.0-266.4) |
| Female | 4 | 4.7 | nc | (nc-nc) |  | Female | 1 | 5.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 20 | 17.9 | 111.4 | (68.0-172.1) |
| Female | 146 | 117.3 | 124.4 | (105.1-146.3) |  | Female | 15 | 15.9 | 94.1 | (52.6-155.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 13.2 | 106.1 | (58.0-178.1) |
| Female | 5 | 3.8 | 133.2 | (42.9-310.8) |  | Female | 12 | 6.5 | 183.7 | (94.8-320.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 34.1 | 70.4 | (45.1-104.8) |  |  |  |  |  |  |
| Female | 29 | 36.3 | 79.8 | (53.4-114.6) |  | Female | 11 | 10.6 | 103.6 | (51.6-185.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 8.0 | 74.8 | (27.3-162.9) |  | Male | 11 | 11.0 | 99.8 | (49.7-178.5) |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 17 | 12.2 | 139.1 | (81.0-222.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 94 | 93.8 | 100.2 | (81.0-122.6) |
| Female | 3 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 16.1 | 86.8 | (47.4-145.6) |  | Male | 9 | 7.5 | 120.3 | (54.9-228.3) |
| Female | 12 | 9.6 | 124.6 | (64.3-217.7) |  | Female | 7 | 4.7 | 147.6 | (59.1-304.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 12.6 | 71.5 | (32.6-135.7) |  | Male | 5 | 7.0 | 71.4 | (23.0-166.7) |
| Female | 7 | 9.4 | 74.7 | (29.9-153.9) |  | Female | 30 | 20.0 | 149.8 | (101.1-213.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 10.0 | 109.9 | (54.8-196.7) |  |  |  |  |  |  |
| Female | 6 | 3.6 | 167.4 | (61.1-364.5) |  | Female | 25 | 25.8 | 96.9 | (62.7-143.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 50 | 56.7 | 88.2 | (65.5-116.3) |  | Male | 390 | 398.2 | 97.9 | (88.5-108.2) |
| Female | 77 | 60.6 | 127.1 | (100.3-158.9) |  | Female | 468 | 415.0 | 112.8 | (102.8-123.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

83

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  | Male | 5 | 3.2 | 155.1 | (50.0-361.9) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 19 | 24.6 | 77.4 | (46.6-120.8) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.3 | 112.6 | (41.1-245.2) |  |  |  |  |  |  |
| Female | 5 | 6.3 | 80.0 | (25.8-186.6) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 19 | 19.4 | 97.9 | (58.9-152.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 3.1 | 162.4 | (52.3-379.0) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 5.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 8.6 | nc | (nc-nc) |  | Male | 54 | 68.0 | 79.5 | (59.7-103.7) |
| Female | 5 | 11.4 | 43.7 | (14.1-101.9) |  | Female | 60 | 80.8 | 74.3 | (56.7-95.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

84

# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 42 | 28.9 | 145.4 | (104.8-196.6) |  | Male | 37 | 16.2 | 228.2 | (160.7-314.6) |
| Female | 15 | 10.4 | 144.8 | (81.0-238.9) |  | Female | 20 | 11.7 | 171.6 | (104.8-265.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 10 | 5.3 | 187.7 | (89.8-345.2) |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 2 | 4.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 15 | 14.2 | 105.5 | (59.0-174.1) |
| Female | 114 | 96.2 | 118.5 | (97.7-142.3) |  | Female | 10 | 13.3 | 75.4 | (36.1-138.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 10.1 | 159.0 | (90.8-258.2) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 3 | 5.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 27.4 | 105.8 | (70.9-152.0) |  |  |  |  |  |  |
| Female | 24 | 28.5 | 84.3 | (54.0-125.5) |  | Female | 13 | 8.6 | 150.4 | (80.0-257.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 6.8 | 146.9 | (70.3-270.2) |  | Male | 17 | 9.5 | 179.1 | (104.3-286.8) |
| Female | 5 | 2.0 | 251.6 | (81.1-587.2) |  | Female | 11 | 10.2 | 107.7 | (53.7-192.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 108 | 81.8 | 132.0 | (108.3-159.4) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 12.6 | 79.6 | (38.1-146.4) |  | Male | 2 | 6.3 | nc | (nc-nc) |
| Female | 6 | 8.2 | 73.1 | (26.7-159.1) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 10.1 | 139.2 | (76.0-233.6) |  | Male | 1 | 4.4 | nc | (nc-nc) |
| Female | 7 | 7.3 | 95.8 | (38.4-197.3) |  | Female | 17 | 13.1 | 129.4 | (75.3-207.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 8.1 | 98.7 | (42.5-194.6) |  |  |  |  |  |  |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 20 | 22.8 | 87.6 | (53.5-135.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 44 | 50.7 | 86.9 | (63.1-116.6) |  | Male | 401 | 331.3 | 121.0 | (109.5-133.5) |
| Female | 54 | 56.3 | 95.9 | (72.1-125.2) |  | Female | 366 | 342.3 | 106.9 | (96.3-118.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

85

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 9.8 | 71.6 | (28.7-147.4) |  | Male | 5 | 5.9 | 84.9 | (27.3-198.0) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.3 | 94.7 | (30.5-220.9) |
| Female | 16 | 29.6 | 54.1 | (30.9-87.9) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 10.2 | 147.0 | (82.2-242.5) |  |  |  |  |  |  |
| Female | 5 | 8.2 | 60.9 | (19.6-142.1) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 30 | 28.7 | 104.4 | (70.4-149.0) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 4.8 | 126.0 | (46.0-274.2) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 5 | 2.4 | 211.3 | (68.1-493.1) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 3 | 5.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 7 | 6.6 | 106.1 | (42.5-218.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 16.9 | 59.2 | (28.4-109.0) |  | Male | 110 | 119.0 | 92.5 | (76.0-111.4) |
| Female | 14 | 14.2 | 98.6 | (53.9-165.5) |  | Female | 75 | 100.3 | 74.7 | (58.8-93.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

86

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 7.1 | 84.4 | (30.8-183.8) |  | Male | 6 | 5.2 | 116.3 | (42.5-253.1) |
| Female | 4 | 2.0 | nc | (nc-nc) |  | Female | 6 | 3.8 | 156.5 | (57.1-340.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 29 | 31.4 | 92.2 | (61.7-132.5) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 8.4 | 59.3 | (19.1-138.3) |  |  |  |  |  |  |
| Female | 5 | 6.5 | 77.0 | (24.8-179.6) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 24 | 28.4 | 84.7 | (54.2-126.0) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 4.7 | 170.2 | (73.3-335.4) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 9 | 6.7 | 134.1 | (61.2-254.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 9 | 7.1 | 126.6 | (57.8-240.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 13.4 | 104.5 | (57.1-175.3) |  | Male | 101 | 105.8 | 95.5 | (77.8-116.0) |
| Female | 11 | 11.8 | 93.3 | (46.5-166.9) |  | Female | 98 | 95.5 | 102.6 | (83.3-125.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

87

# Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 7.6 | nc | (nc-nc) |  | Male | 11 | 4.7 | 234.9 | (117.1-420.4) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.2 | 168.7 | (67.6-347.5) |
| Female | 27 | 25.1 | 107.4 | (70.8-156.3) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 7.9 | 75.7 | (27.6-164.7) |  |  |  |  |  |  |
| Female | 5 | 6.2 | 80.2 | (25.9-187.2) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 27 | 23.4 | 115.4 | (76.0-167.9) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 4 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 5 | 4.3 | 115.1 | (37.1-268.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 5.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 13.6 | 58.8 | (25.3-115.8) |  | Male | 92 | 94.8 | 97.0 | (78.2-119.0) |
| Female | 6 | 11.5 | 52.2 | (19.1-113.7) |  | Female | 63 | 81.2 | 77.6 | (59.6-99.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

88

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 40 | 29.9 | 133.9 | (95.6-182.3) |  | Male | 10 | 20.1 | 49.7 | (23.8-91.4) |
| Female | 16 | 10.4 | 153.7 | (87.8-249.5) |  | Female | 15 | 15.8 | 95.0 | (53.2-156.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 6.3 | 110.7 | (44.3-228.0) |  | Male | 7 | 6.3 | 111.7 | (44.7-230.1) |
| Female | 3 | 4.9 | nc | (nc-nc) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 15 | 17.9 | 83.7 | (46.8-138.1) |
| Female | 138 | 123.2 | 112.0 | (94.1-132.3) |  | Female | 10 | 15.0 | 66.7 | (32.0-122.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 15.2 | 52.8 | (22.7-104.0) |
| Female | 5 | 4.3 | 115.3 | (37.2-269.1) |  | Female | 10 | 6.4 | 155.9 | (74.6-286.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 33.3 | 114.2 | (80.8-156.8) |  |  |  |  |  |  |
| Female | 48 | 31.8 | 151.0 | (111.4-200.3) |  | Female | 12 | 10.8 | 110.6 | (57.1-193.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 8.4 | 155.5 | (82.7-266.0) |  | Male | 7 | 10.8 | 64.7 | (25.9-133.4) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 12 | 10.4 | 115.0 | (59.4-200.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 99 | 108.7 | 91.1 | (74.0-110.9) |
| Female | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 17.5 | 114.0 | (69.6-176.0) |  | Male | 6 | 7.2 | 83.8 | (30.6-182.3) |
| Female | 7 | 9.6 | 73.0 | (29.3-150.5) |  | Female | 5 | 4.1 | 123.3 | (39.7-287.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 4.9 | 164.1 | (70.6-323.3) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 12.5 | 144.2 | (85.4-228.0) |  | Male | 7 | 8.3 | 84.6 | (33.9-174.4) |
| Female | 10 | 8.7 | 114.4 | (54.8-210.5) |  | Female | 28 | 23.7 | 118.0 | (78.4-170.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 11.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 3.4 | 145.9 | (47.0-340.4) |  | Female | 13 | 28.2 | 46.1 | (24.5-78.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 61 | 54.7 | 111.6 | (85.4-143.4) |  | Male | 408 | 412.2 | 99.0 | (89.6-109.1) |
| Female | 75 | 55.9 | 134.1 | (105.5-168.1) |  | Female | 461 | 408.6 | 112.8 | (102.8-123.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

89

# Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 11.2 | 107.1 | (55.3-187.0) |  | Male | 5 | 7.3 | 68.6 | (22.1-160.0) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 2 | 5.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 4 | 6.6 | nc | (nc-nc) |
| Female | 42 | 39.6 | 106.0 | (76.4-143.3) |  | Female | 5 | 4.6 | 108.4 | (34.9-252.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 5.1 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 12.0 | 100.1 | (51.7-174.9) |  |  |  |  |  |  |
| Female | 11 | 9.5 | 115.4 | (57.6-206.6) |  | Female | 8 | 3.4 | 233.5 | (100.5-460.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 5 | 3.9 | 129.8 | (41.8-303.0) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 33 | 34.5 | 95.5 | (65.8-134.2) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 6.1 | 132.2 | (56.9-260.5) |  | Male | 5 | 2.6 | 190.4 | (61.3-444.2) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 4.6 | 194.5 | (88.8-369.2) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 5 | 2.7 | 185.0 | (59.6-431.7) |  | Female | 11 | 8.0 | 138.1 | (68.8-247.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 17 | 8.9 | 190.3 | (110.8-304.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 19.9 | 130.5 | (85.2-191.2) |  | Male | 149 | 144.7 | 103.0 | (87.1-120.9) |
| Female | 26 | 17.0 | 152.6 | (99.6-223.6) |  | Female | 158 | 128.1 | 123.3 | (104.9-144.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

90

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 18 | 14.1 | 127.6 | (75.6-201.7) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 3.5 | 144.6 | (46.6-337.5) |  |  |  |  |  |  |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 12.3 | 57.1 | (22.9-117.7) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.5 | nc | (nc-nc) |  | Male | 39 | 43.3 | 90.1 | (64.0-123.1) |
| Female | 8 | 5.7 | 140.2 | (60.4-276.3) |  | Female | 45 | 45.1 | 99.8 | (72.8-133.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

91

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 18.0 | 138.6 | (89.7-204.6) |  | Male | 29 | 11.3 | 255.7 | (171.2-367.3) |
| Female | 1 | 6.7 | nc | (nc-nc) |  | Female | 15 | 9.1 | 164.4 | (91.9-271.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 7 | 3.7 | 189.8 | (76.0-391.0) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 18 | 10.2 | 176.6 | (104.6-279.1) |
| Female | 82 | 74.5 | 110.0 | (87.5-136.5) |  | Female | 4 | 9.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 8.4 | 71.4 | (26.1-155.5) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 19.3 | 51.9 | (24.8-95.4) |  |  |  |  |  |  |
| Female | 14 | 20.4 | 68.5 | (37.4-114.9) |  | Female | 6 | 6.6 | 90.7 | (33.1-197.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.9 | 122.9 | (44.9-267.5) |  | Male | 5 | 6.3 | 78.8 | (25.4-183.9) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 6 | 6.8 | 88.4 | (32.3-192.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 73 | 62.9 | 116.1 | (91.0-146.0) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 9.9 | 161.3 | (92.2-262.0) |  | Male | 0 | 4.2 | nc | (nc-nc) |
| Female | 3 | 5.8 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.1 | 99.2 | (39.7-204.4) |  | Male | 0 | 4.2 | nc | (nc-nc) |
| Female | 4 | 5.3 | nc | (nc-nc) |  | Female | 10 | 12.5 | 79.8 | (38.2-146.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 6.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 8 | 17.0 | 47.1 | (20.3-92.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 32.4 | 86.4 | (57.4-124.8) |  | Male | 261 | 237.0 | 110.1 | (97.2-124.4) |
| Female | 17 | 34.9 | 48.6 | (28.3-77.9) |  | Female | 207 | 249.3 | 83.0 | (72.1-95.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

92

# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 12.2 | 130.9 | (74.8-212.6) |  | Male | 10 | 8.4 | 119.5 | (57.2-219.8) |
| Female | 6 | 5.8 | 102.6 | (37.5-223.4) |  | Female | 8 | 8.3 | 96.2 | (41.4-189.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.6 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 0 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 8 | 7.5 | 106.3 | (45.8-209.5) |
| Female | 47 | 66.9 | 70.3 | (51.6-93.4) |  | Female | 11 | 8.3 | 132.8 | (66.2-237.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 6.4 | 124.6 | (53.6-245.5) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 14.1 | 121.0 | (70.4-193.7) |  |  |  |  |  |  |
| Female | 11 | 17.7 | 62.3 | (31.0-111.4) |  | Female | 6 | 5.9 | 101.5 | (37.1-220.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.4 | 175.2 | (64.0-381.3) |  | Male | 2 | 4.5 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 8 | 5.8 | 137.2 | (59.1-270.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 46 | 44.7 | 102.8 | (75.3-137.2) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 7.5 | 160.5 | (82.8-280.3) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 4 | 5.2 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.2 | nc | (nc-nc) |  | Male | 5 | 3.6 | 138.3 | (44.6-322.7) |
| Female | 4 | 4.7 | nc | (nc-nc) |  | Female | 11 | 12.1 | 91.1 | (45.4-163.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.6 | 109.1 | (35.2-254.6) |  |  |  |  |  |  |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 11 | 15.3 | 71.9 | (35.8-128.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 22.4 | 120.7 | (79.6-175.7) |  | Male | 192 | 171.0 | 112.3 | (97.0-129.3) |
| Female | 24 | 31.6 | 75.8 | (48.6-112.8) |  | Female | 183 | 223.2 | 82.0 | (70.5-94.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

93

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 8 | 10.0 | 80.0 | (34.4-157.6) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 9.5 | 84.4 | (36.4-166.4) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 4.7 | nc | (nc-nc) |  | Male | 29 | 35.3 | 82.1 | (55.0-117.9) |
| Female | 5 | 4.6 | 108.6 | (35.0-253.5) |  | Female | 29 | 32.8 | 88.4 | (59.2-127.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

94

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 20.2 | 89.2 | (52.8-141.0) |  | Male | 19 | 12.3 | 154.1 | (92.7-240.6) |
| Female | 5 | 8.6 | 58.3 | (18.8-136.0) |  | Female | 10 | 10.4 | 96.2 | (46.1-177.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 14 | 11.1 | 125.9 | (68.8-211.2) |
| Female | 75 | 80.7 | 92.9 | (73.1-116.5) |  | Female | 9 | 11.3 | 80.0 | (36.5-151.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 8.7 | 104.0 | (47.5-197.4) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 5 | 4.6 | 108.7 | (35.0-253.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 21.4 | 98.2 | (60.8-150.1) |  |  |  |  |  |  |
| Female | 23 | 25.8 | 89.0 | (56.4-133.5) |  | Female | 12 | 7.4 | 163.0 | (84.1-284.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.1 | nc | (nc-nc) |  | Male | 5 | 6.9 | 72.1 | (23.2-168.4) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 11 | 8.8 | 125.2 | (62.4-224.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 53 | 63.2 | 83.8 | (62.8-109.6) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 10.3 | 126.2 | (67.1-215.9) |  | Male | 5 | 4.6 | 107.8 | (34.7-251.5) |
| Female | 8 | 6.7 | 119.9 | (51.6-236.3) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.7 | 90.5 | (36.3-186.5) |  | Male | 2 | 4.4 | nc | (nc-nc) |
| Female | 2 | 6.6 | nc | (nc-nc) |  | Female | 8 | 12.8 | 62.4 | (26.9-123.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 16 | 18.0 | 88.8 | (50.7-144.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 36 | 34.9 | 103.0 | (72.1-142.6) |  | Male | 234 | 252.4 | 92.7 | (81.2-105.4) |
| Female | 51 | 42.7 | 119.5 | (89.0-157.1) |  | Female | 273 | 288.8 | 94.5 | (83.7-106.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

95

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 11.1 | 89.9 | (43.0-165.3) |  | Male | 8 | 6.4 | 124.7 | (53.7-245.8) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 13 | 4.2 | 307.7 | (163.7-526.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 5.6 | nc | (nc-nc) |
| Female | 45 | 35.8 | 125.8 | (91.8-168.4) |  | Female | 7 | 4.7 | 149.6 | (59.9-308.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 10.8 | 101.6 | (50.7-181.9) |  |  |  |  |  |  |
| Female | 12 | 9.9 | 121.5 | (62.7-212.2) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 6 | 3.5 | 169.5 | (61.9-369.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 42 | 36.6 | 114.8 | (82.7-155.2) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 3.9 | 230.0 | (104.9-436.6) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 7 | 8.7 | 80.7 | (32.3-166.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 20.0 | 124.9 | (80.8-184.4) |  | Male | 141 | 135.5 | 104.0 | (87.6-122.7) |
| Female | 14 | 19.9 | 70.4 | (38.4-118.0) |  | Female | 140 | 123.3 | 113.5 | (95.5-134.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

96

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 18.4 | 49.0 | (22.3-93.0) |  | Male | 9 | 12.0 | 74.9 | (34.2-142.1) |
| Female | 2 | 7.0 | nc | (nc-nc) |  | Female | 7 | 9.7 | 72.3 | (29.0-149.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 9 | 10.7 | 84.5 | (38.5-160.3) |
| Female | 66 | 73.9 | 89.3 | (69.1-113.6) |  | Female | 11 | 9.6 | 114.6 | (57.1-205.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 8.8 | 113.8 | (54.5-209.2) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 7 | 4.0 | 174.8 | (70.0-360.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 20.1 | 159.3 | (108.9-224.8) |  |  |  |  |  |  |
| Female | 25 | 21.0 | 119.1 | (77.0-175.8) |  | Female | 3 | 6.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  | Male | 4 | 6.5 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 9 | 6.9 | 129.7 | (59.2-246.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 52 | 62.2 | 83.6 | (62.4-109.6) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 10.1 | 69.0 | (27.6-142.2) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 8 | 6.0 | 134.0 | (57.7-264.0) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.3 | 95.4 | (38.2-196.7) |  | Male | 1 | 4.7 | nc | (nc-nc) |
| Female | 3 | 5.5 | nc | (nc-nc) |  | Female | 8 | 13.8 | 58.1 | (25.0-114.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 19 | 16.8 | 113.3 | (68.2-176.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 32.8 | 88.3 | (59.1-126.8) |  | Male | 206 | 243.5 | 84.6 | (73.4-97.0) |
| Female | 34 | 36.4 | 93.3 | (64.6-130.4) |  | Female | 231 | 254.8 | 90.7 | (79.3-103.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

97

# Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 20.9 | 115.1 | (73.7-171.2) |  | Male | 19 | 14.2 | 134.1 | (80.7-209.5) |
| Female | 9 | 7.2 | 124.2 | (56.7-235.8) |  | Female | 18 | 11.4 | 157.6 | (93.4-249.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.6 | 131.8 | (48.1-286.9) |  | Male | 5 | 4.4 | 112.5 | (36.3-262.5) |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 8 | 12.7 | 62.9 | (27.1-123.9) |
| Female | 117 | 89.0 | 131.5 | (108.8-157.6) |  | Female | 14 | 10.7 | 130.8 | (71.5-219.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 10.8 | 92.4 | (44.2-169.9) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 23.3 | 77.3 | (45.8-122.2) |  |  |  |  |  |  |
| Female | 31 | 22.3 | 139.0 | (94.4-197.3) |  | Female | 9 | 7.8 | 115.4 | (52.7-219.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 5.9 | 101.0 | (36.9-219.9) |  | Male | 8 | 7.6 | 105.6 | (45.5-208.1) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 8 | 7.2 | 111.3 | (47.9-219.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 71 | 78.5 | 90.4 | (70.6-114.1) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 12.6 | 118.8 | (66.4-195.9) |  | Male | 5 | 5.0 | 99.2 | (32.0-231.4) |
| Female | 6 | 6.8 | 87.7 | (32.0-191.0) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 8.9 | 146.6 | (78.0-250.7) |  | Male | 10 | 6.0 | 167.1 | (80.0-307.4) |
| Female | 7 | 6.3 | 111.3 | (44.6-229.3) |  | Female | 19 | 17.9 | 106.2 | (63.9-165.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 8.0 | 125.5 | (60.1-230.8) |  |  |  |  |  |  |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 15 | 20.1 | 74.5 | (41.7-122.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 38.6 | 121.7 | (89.4-161.8) |  | Male | 312 | 293.4 | 106.3 | (94.9-118.8) |
| Female | 47 | 39.2 | 119.8 | (88.0-159.4) |  | Female | 351 | 292.5 | 120.0 | (107.8-133.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

98

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.0 | 99.3 | (39.8-204.7) |  | Male | 12 | 4.5 | 269.2 | (138.9-470.3) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 24 | 19.0 | 126.1 | (80.8-187.7) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 7.5 | 120.2 | (54.9-228.3) |  |  |  |  |  |  |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 30 | 25.6 | 117.0 | (78.9-167.0) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 6 | 3.3 | 180.9 | (66.1-393.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 12.7 | 39.5 | (12.7-92.1) |  | Male | 87 | 93.7 | 92.9 | (74.4-114.6) |
| Female | 11 | 8.8 | 125.5 | (62.6-224.6) |  | Female | 71 | 62.7 | 113.3 | (88.5-142.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

99

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 4 | 7.9 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 2.2 | 229.2 | (73.9-534.9) |  |  |  |  |  |  |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 7.7 | 64.5 | (20.8-150.6) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 21 | 27.7 | 75.8 | (46.9-115.8) |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 16 | 27.4 | 58.4 | (33.4-94.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

100

# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 4 | 7.3 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 6.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 15 | 23.9 | 62.7 | (35.1-103.4) |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 16 | 24.7 | 64.9 | (37.1-105.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

101

# Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 3.9 | 127.7 | (41.1-298.0) |  | Male | 5 | 2.6 | 190.7 | (61.4-445.0) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 3 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 13 | 16.6 | 78.5 | (41.8-134.2) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 2.0 | 246.1 | (79.3-574.3) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 5 | 1.4 | 348.4 | (112.3-813.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 15.0 | 46.6 | (18.7-96.0) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 7.2 | 138.1 | (66.1-254.1) |  | Male | 55 | 54.7 | 100.6 | (75.7-130.9) |
| Female | 8 | 7.3 | 109.7 | (47.2-216.1) |  | Female | 54 | 52.7 | 102.4 | (77.0-133.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

102

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 37.7 | 76.9 | (51.5-110.5) |  | Male | 19 | 25.2 | 75.3 | (45.3-117.5) |
| Female | 10 | 13.6 | 73.7 | (35.3-135.6) |  | Female | 6 | 20.8 | 28.9 | (10.6-62.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 8.1 | nc | (nc-nc) |  | Male | 9 | 7.7 | 117.6 | (53.7-223.3) |
| Female | 3 | 6.4 | nc | (nc-nc) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 15 | 22.5 | 66.6 | (37.3-109.9) |
| Female | 137 | 153.3 | 89.4 | (75.0-105.6) |  | Female | 18 | 19.3 | 93.3 | (55.2-147.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 17.7 | 101.9 | (60.4-161.1) |
| Female | 15 | 5.8 | 258.6 | (144.6-426.5) |  | Female | 9 | 8.0 | 112.0 | (51.1-212.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 41.6 | 91.4 | (64.6-125.4) |  |  |  |  |  |  |
| Female | 33 | 42.3 | 78.0 | (53.7-109.6) |  | Female | 10 | 13.6 | 73.3 | (35.1-134.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 9.8 | 112.7 | (56.2-201.6) |  | Male | 11 | 13.2 | 83.5 | (41.6-149.5) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 16 | 13.6 | 118.0 | (67.4-191.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 104 | 118.2 | 88.0 | (71.9-106.6) |
| Female | 5 | 2.9 | 173.4 | (55.9-404.6) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 21.0 | 119.3 | (77.2-176.1) |  | Male | 15 | 8.9 | 168.3 | (94.1-277.6) |
| Female | 18 | 12.2 | 147.5 | (87.4-233.2) |  | Female | 6 | 5.4 | 110.9 | (40.5-241.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.6 | 106.3 | (38.8-231.3) |  | Male | 7 | 7.4 | 95.2 | (38.1-196.1) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 16.1 | 62.3 | (29.8-114.5) |  | Male | 8 | 10.5 | 76.3 | (32.9-150.3) |
| Female | 13 | 11.7 | 110.7 | (58.9-189.3) |  | Female | 24 | 32.3 | 74.2 | (47.6-110.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 12.9 | 115.9 | (64.8-191.1) |  |  |  |  |  |  |
| Female | 9 | 4.3 | 211.5 | (96.5-401.5) |  | Female | 27 | 33.3 | 81.1 | (53.5-118.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 79 | 66.8 | 118.2 | (93.6-147.3) |  | Male | 454 | 496.0 | 91.5 | (83.3-100.3) |
| Female | 98 | 70.6 | 138.8 | (112.7-169.2) |  | Female | 500 | 521.9 | 95.8 | (87.6-104.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

103

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 20.0 | 144.6 | (96.9-207.7) |  | Male | 6 | 12.7 | 47.4 | (17.3-103.1) |
| Female | 16 | 8.3 | 193.2 | (110.3-313.7) |  | Female | 11 | 10.6 | 103.9 | (51.8-185.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 5 | 4.0 | 123.9 | (39.9-289.1) |
| Female | 5 | 3.2 | 155.3 | (50.0-362.3) |  | Female | 0 | 3.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 7 | 11.3 | 61.9 | (24.8-127.6) |
| Female | 79 | 81.1 | 97.4 | (77.1-121.4) |  | Female | 15 | 11.0 | 136.5 | (76.4-225.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 9.3 | 64.6 | (23.6-140.6) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 21.5 | 60.5 | (32.2-103.4) |  |  |  |  |  |  |
| Female | 21 | 25.1 | 83.8 | (51.9-128.1) |  | Female | 12 | 7.5 | 160.5 | (82.9-280.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 3 | 7.1 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 10 | 8.5 | 118.0 | (56.5-217.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 75 | 70.0 | 107.2 | (84.3-134.4) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 10.9 | 156.1 | (90.9-249.9) |  | Male | 6 | 4.7 | 128.1 | (46.8-278.7) |
| Female | 10 | 6.6 | 151.0 | (72.3-277.6) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 7.7 | 130.3 | (62.4-239.7) |  | Male | 5 | 4.7 | 105.6 | (34.0-246.3) |
| Female | 9 | 6.5 | 138.8 | (63.3-263.5) |  | Female | 14 | 13.8 | 101.7 | (55.6-170.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 17 | 18.5 | 92.0 | (53.6-147.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 50 | 35.8 | 139.5 | (103.5-183.9) |  | Male | 274 | 263.0 | 104.2 | (92.2-117.3) |
| Female | 46 | 40.9 | 112.5 | (82.4-150.1) |  | Female | 300 | 286.4 | 104.7 | (93.2-117.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

104

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 102 | 88.3 | 115.6 | (94.2-140.3) |  | Male | 29 | 57.1 | 50.8 | (34.0-73.0) |
| Female | 37 | 38.0 | 97.3 | (68.5-134.1) |  | Female | 25 | 51.6 | 48.4 | (31.3-71.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 18 | 17.5 | 102.9 | (60.9-162.6) |  | Male | 13 | 17.7 | 73.4 | (39.1-125.6) |
| Female | 11 | 16.1 | 68.3 | (34.1-122.2) |  | Female | 16 | 16.8 | 95.0 | (54.3-154.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 44 | 51.1 | 86.1 | (62.6-115.6) |
| Female | 297 | 390.4 | 76.1 | (67.7-85.2) |  | Female | 54 | 52.0 | 103.9 | (78.1-135.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 39 | 40.6 | 96.0 | (68.3-131.3) |
| Female | 17 | 13.3 | 127.8 | (74.4-204.7) |  | Female | 15 | 21.6 | 69.5 | (38.9-114.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 115 | 95.4 | 120.6 | (99.5-144.7) |  |  |  |  |  |  |
| Female | 119 | 114.8 | 103.6 | (85.8-124.0) |  | Female | 19 | 35.5 | 53.5 | (32.2-83.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 18 | 23.1 | 77.8 | (46.1-122.9) |  | Male | 33 | 30.9 | 106.7 | (73.4-149.8) |
| Female | 4 | 7.3 | nc | (nc-nc) |  | Female | 39 | 38.5 | 101.2 | (72.0-138.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 12 | 7.2 | 165.8 | (85.5-289.6) |  | Male | 287 | 292.7 | 98.1 | (87.0-110.1) |
| Female | 6 | 6.5 | 92.4 | (33.7-201.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 47 | 48.3 | 97.3 | (71.5-129.5) |  | Male | 36 | 20.7 | 173.7 | (121.6-240.5) |
| Female | 31 | 31.7 | 97.7 | (66.4-138.7) |  | Female | 29 | 14.9 | 194.5 | (130.8-279.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 23 | 13.5 | 170.8 | (108.2-256.3) |  | Male | 14 | 13.6 | 103.1 | (56.3-173.0) |
| Female | 12 | 4.8 | 251.7 | (129.9-439.8) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 34 | 36.0 | 94.4 | (65.3-131.9) |  | Male | 18 | 22.4 | 80.3 | (47.6-126.9) |
| Female | 34 | 30.9 | 110.0 | (76.2-153.8) |  | Female | 77 | 72.3 | 106.5 | (84.0-133.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 32 | 30.1 | 106.5 | (72.8-150.3) |  |  |  |  |  |  |
| Female | 14 | 11.7 | 119.7 | (65.4-200.9) |  | Female | 99 | 87.6 | 113.1 | (91.9-137.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 231 | 157.4 | 146.8 | (128.4-167.0) |  | Male | 1243 | 1157.9 | 107.3 | (101.5-113.5) |
| Female | 218 | 195.0 | 111.8 | (97.4-127.7) |  | Female | 1311 | 1365.9 | 96.0 | (90.9-101.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

105

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 54 | 58.7 | 91.9 | (69.1-119.9) |  | Male | 35 | 33.7 | 103.9 | (72.3-144.4) |
| Female | 13 | 21.0 | 61.9 | (32.9-105.8) |  | Female | 41 | 24.5 | 167.1 | (119.9-226.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 8.6 | 162.9 | (89.0-273.4) |  | Male | 7 | 11.0 | 63.8 | (25.6-131.5) |
| Female | 9 | 7.4 | 121.4 | (55.4-230.5) |  | Female | 7 | 9.2 | 76.0 | (30.4-156.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 31 | 29.8 | 104.1 | (70.7-147.8) |
| Female | 216 | 200.0 | 108.0 | (94.1-123.4) |  | Female | 24 | 27.2 | 88.1 | (56.4-131.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 22.0 | 109.1 | (69.9-162.3) |
| Female | 3 | 5.6 | nc | (nc-nc) |  | Female | 7 | 11.3 | 61.9 | (24.8-127.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 53 | 57.6 | 92.0 | (68.9-120.4) |  |  |  |  |  |  |
| Female | 52 | 59.9 | 86.9 | (64.9-113.9) |  | Female | 24 | 18.2 | 132.2 | (84.7-196.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 14.3 | 91.2 | (48.5-155.9) |  | Male | 15 | 19.7 | 76.1 | (42.6-125.5) |
| Female | 6 | 4.0 | 149.4 | (54.6-325.3) |  | Female | 17 | 21.0 | 81.1 | (47.2-129.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 195 | 175.6 | 111.1 | (96.0-127.8) |
| Female | 1 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 26.8 | 111.8 | (75.4-159.6) |  | Male | 10 | 13.0 | 77.1 | (36.9-141.9) |
| Female | 16 | 16.8 | 95.4 | (54.5-154.9) |  | Female | 5 | 7.7 | 64.7 | (20.8-151.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 8.2 | 110.1 | (50.2-209.0) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 20.9 | 86.0 | (50.9-135.9) |  | Male | 7 | 9.9 | 70.5 | (28.3-145.4) |
| Female | 9 | 15.2 | 59.3 | (27.1-112.6) |  | Female | 14 | 28.8 | 48.6 | (26.5-81.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 17.3 | 98.5 | (57.3-157.6) |  |  |  |  |  |  |
| Female | 3 | 6.3 | nc | (nc-nc) |  | Female | 39 | 47.2 | 82.6 | (58.7-112.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 65 | 103.3 | 62.9 | (48.6-80.2) |  | Male | 667 | 694.7 | 96.0 | (88.9-103.6) |
| Female | 109 | 110.8 | 98.4 | (80.8-118.7) |  | Female | 667 | 706.2 | 94.4 | (87.4-101.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

106

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 41 | 39.6 | 103.4 | (74.2-140.3) |  | Male | 15 | 25.6 | 58.5 | (32.7-96.5) |
| Female | 14 | 14.9 | 93.8 | (51.3-157.5) |  | Female | 13 | 20.7 | 62.7 | (33.4-107.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 8.1 | nc | (nc-nc) |  | Male | 12 | 8.0 | 150.2 | (77.5-262.5) |
| Female | 9 | 6.5 | 138.4 | (63.1-262.7) |  | Female | 7 | 6.6 | 105.9 | (42.4-218.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 16 | 22.9 | 69.7 | (39.8-113.2) |
| Female | 133 | 155.9 | 85.3 | (71.4-101.1) |  | Female | 15 | 20.4 | 73.6 | (41.1-121.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 18.0 | 133.6 | (85.5-198.7) |
| Female | 9 | 5.3 | 169.5 | (77.3-321.8) |  | Female | 11 | 8.5 | 129.4 | (64.5-231.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 42.3 | 80.3 | (55.6-112.2) |  |  |  |  |  |  |
| Female | 43 | 44.4 | 96.9 | (70.1-130.5) |  | Female | 16 | 14.1 | 113.2 | (64.6-183.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 10.4 | 86.9 | (39.7-165.0) |  | Male | 11 | 13.8 | 79.6 | (39.7-142.5) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 7 | 15.0 | 46.8 | (18.7-96.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 3.5 | 142.1 | (45.8-331.6) |  | Male | 101 | 129.7 | 77.9 | (63.4-94.6) |
| Female | 0 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 19 | 21.5 | 88.6 | (53.3-138.3) |  | Male | 14 | 9.2 | 151.8 | (82.9-254.8) |
| Female | 9 | 12.7 | 70.7 | (32.3-134.3) |  | Female | 5 | 5.7 | 87.0 | (28.0-203.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 6.0 | nc | (nc-nc) |  | Male | 6 | 6.5 | 92.9 | (33.9-202.2) |
| Female | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 16.5 | 72.9 | (37.6-127.3) |  | Male | 4 | 10.0 | nc | (nc-nc) |
| Female | 11 | 12.2 | 90.0 | (44.8-161.0) |  | Female | 27 | 29.5 | 91.6 | (60.3-133.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 13.5 | 96.3 | (51.2-164.7) |  |  |  |  |  |  |
| Female | 5 | 4.6 | 108.3 | (34.9-252.7) |  | Female | 29 | 35.3 | 82.1 | (55.0-118.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 95 | 71.2 | 133.4 | (107.9-163.1) |  | Male | 478 | 518.8 | 92.1 | (84.1-100.8) |
| Female | 84 | 78.1 | 107.6 | (85.8-133.2) |  | Female | 492 | 542.7 | 90.7 | (82.8-99.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

107

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 9 | 9.7 | 92.6 | (42.3-175.8) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 11 | 12.1 | 90.9 | (45.3-162.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

108

# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 17.5 | 68.5 | (35.4-119.7) |  | Male | 22 | 11.4 | 193.6 | (121.3-293.2) |
| Female | 4 | 6.2 | nc | (nc-nc) |  | Female | 12 | 9.2 | 130.3 | (67.2-227.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.5 | 144.2 | (46.5-336.6) |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 12 | 10.2 | 117.4 | (60.6-205.0) |
| Female | 92 | 73.9 | 124.5 | (100.4-152.7) |  | Female | 7 | 8.9 | 78.2 | (31.3-161.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.3 | 84.8 | (34.0-174.8) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 0 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 19.3 | 103.6 | (63.2-160.0) |  |  |  |  |  |  |
| Female | 20 | 18.4 | 108.6 | (66.3-167.7) |  | Female | 10 | 6.4 | 155.1 | (74.2-285.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.6 | 107.5 | (34.7-250.9) |  | Male | 3 | 6.2 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 6 | 6.1 | 98.9 | (36.1-215.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 1.4 | 365.9 | (117.9-853.9) |  | Male | 66 | 58.0 | 113.8 | (88.0-144.7) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 9.7 | 92.5 | (42.2-175.6) |  | Male | 7 | 4.1 | 169.6 | (68.0-349.5) |
| Female | 6 | 5.8 | 104.2 | (38.1-226.9) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 7.1 | 112.5 | (48.4-221.6) |  | Male | 8 | 4.5 | 177.0 | (76.2-348.7) |
| Female | 7 | 5.1 | 137.4 | (55.1-283.2) |  | Female | 19 | 13.8 | 137.9 | (83.0-215.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 21 | 17.1 | 122.6 | (75.9-187.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 31.1 | 103.0 | (70.4-145.4) |  | Male | 251 | 230.5 | 108.9 | (95.8-123.2) |
| Female | 35 | 34.3 | 102.0 | (71.0-141.8) |  | Female | 276 | 243.4 | 113.4 | (100.4-127.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

109

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 56 | 66.5 | 84.2 | (63.6-109.4) |  | Male | 42 | 43.6 | 96.3 | (69.4-130.1) |
| Female | 29 | 26.0 | 111.6 | (74.7-160.3) |  | Female | 29 | 37.5 | 77.4 | (51.8-111.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 13.4 | 81.9 | (40.8-146.5) |  | Male | 17 | 13.5 | 126.3 | (73.5-202.2) |
| Female | 5 | 11.7 | 42.6 | (13.7-99.3) |  | Female | 13 | 11.6 | 112.1 | (59.6-191.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 42 | 39.0 | 107.8 | (77.7-145.7) |
| Female | 273 | 282.1 | 96.8 | (85.6-109.0) |  | Female | 31 | 36.2 | 85.7 | (58.2-121.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 31 | 30.8 | 100.6 | (68.3-142.8) |
| Female | 18 | 10.1 | 177.8 | (105.3-281.1) |  | Female | 7 | 15.1 | 46.3 | (18.6-95.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 74 | 72.4 | 102.2 | (80.3-128.4) |  |  |  |  |  |  |
| Female | 85 | 79.1 | 107.4 | (85.8-132.8) |  | Female | 28 | 25.3 | 110.7 | (73.5-160.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 15 | 17.4 | 86.3 | (48.3-142.4) |  | Male | 29 | 23.3 | 124.6 | (83.4-178.9) |
| Female | 7 | 5.0 | 140.4 | (56.3-289.3) |  | Female | 29 | 26.1 | 110.9 | (74.3-159.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  | Male | 197 | 216.7 | 90.9 | (78.7-104.5) |
| Female | 9 | 5.0 | 181.6 | (82.9-344.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 46 | 36.7 | 125.2 | (91.6-167.0) |  | Male | 22 | 15.7 | 140.1 | (87.8-212.1) |
| Female | 15 | 22.6 | 66.5 | (37.2-109.6) |  | Female | 11 | 10.2 | 107.4 | (53.5-192.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 10.2 | nc | (nc-nc) |  | Male | 9 | 11.0 | 81.9 | (37.4-155.6) |
| Female | 3 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 29 | 27.4 | 105.9 | (70.9-152.1) |  | Male | 22 | 17.6 | 125.2 | (78.5-189.6) |
| Female | 21 | 21.8 | 96.4 | (59.6-147.3) |  | Female | 56 | 55.6 | 100.7 | (76.1-130.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 28 | 22.8 | 122.6 | (81.4-177.2) |  |  |  |  |  |  |
| Female | 8 | 8.1 | 98.9 | (42.6-194.8) |  | Female | 56 | 62.7 | 89.3 | (67.5-116.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 109 | 117.7 | 92.6 | (76.0-111.7) |  | Male | 848 | 873.4 | 97.1 | (90.7-103.8) |
| Female | 138 | 133.9 | 103.1 | (86.6-121.8) |  | Female | 969 | 968.3 | 100.1 | (93.9-106.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

110

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 27.0 | 103.7 | (68.9-149.9) |  | Male | 16 | 18.4 | 86.8 | (49.6-141.0) |
| Female | 9 | 9.9 | 91.2 | (41.6-173.1) |  | Female | 16 | 15.5 | 103.0 | (58.9-167.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 6.1 | 82.1 | (26.5-191.7) |  | Male | 9 | 5.7 | 158.1 | (72.1-300.1) |
| Female | 5 | 5.0 | 100.8 | (32.5-235.2) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 14 | 16.6 | 84.1 | (46.0-141.2) |
| Female | 130 | 121.4 | 107.1 | (89.5-127.2) |  | Female | 14 | 14.4 | 97.3 | (53.2-163.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 13.7 | 123.8 | (72.1-198.2) |
| Female | 6 | 4.4 | 136.0 | (49.7-296.0) |  | Female | 3 | 6.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 30.7 | 81.4 | (52.7-120.2) |  |  |  |  |  |  |
| Female | 30 | 30.9 | 97.2 | (65.6-138.7) |  | Female | 10 | 10.6 | 94.7 | (45.3-174.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 7.4 | 149.2 | (74.4-267.0) |  | Male | 13 | 9.7 | 133.7 | (71.1-228.7) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 7 | 9.8 | 71.1 | (28.5-146.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 92 | 93.3 | 98.6 | (79.5-120.9) |
| Female | 6 | 2.0 | 294.6 | (107.6-641.2) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 16.1 | 99.1 | (56.6-161.0) |  | Male | 7 | 6.5 | 107.1 | (42.9-220.8) |
| Female | 14 | 9.3 | 150.7 | (82.3-252.8) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 4.3 | 230.3 | (110.3-423.6) |  | Male | 8 | 4.6 | 174.8 | (75.3-344.5) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 11.8 | 110.4 | (58.7-188.8) |  | Male | 13 | 7.9 | 164.7 | (87.6-281.7) |
| Female | 5 | 8.6 | 58.1 | (18.7-135.6) |  | Female | 31 | 24.5 | 126.4 | (85.9-179.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 9.9 | 101.0 | (48.3-185.7) |  |  |  |  |  |  |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 32 | 26.6 | 120.3 | (82.2-169.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 43 | 49.0 | 87.7 | (63.4-118.1) |  | Male | 377 | 371.3 | 101.5 | (91.5-112.3) |
| Female | 38 | 52.9 | 71.8 | (50.8-98.6) |  | Female | 392 | 397.7 | 98.6 | (89.1-108.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

111